Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 161

1.

Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 1.

Wang W, Shangguan S, Qiu N, Hu C, Zhang L, Hu Y.

Bioorg Med Chem. 2013 Jun 1;21(11):2879-85. doi: 10.1016/j.bmc.2013.03.061.

PMID:
23601819
2.

Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 2.

Wang W, Lv D, Qiu N, Zhang L, Hu C, Hu Y.

Bioorg Med Chem. 2013 Jun 1;21(11):2886-94. doi: 10.1016/j.bmc.2013.03.070.

PMID:
23611770
3.

Design, synthesis, and biological evaluation of imidazoline derivatives as p53-MDM2 binding inhibitors.

Hu C, Li X, Wang W, Zhang L, Tao L, Dong X, Sheng R, Yang B, Hu Y.

Bioorg Med Chem. 2011 Sep 15;19(18):5454-61. doi: 10.1016/j.bmc.2011.07.050.

PMID:
21855354
4.

Structure-activity relationship and antitumor activity of thio-benzodiazepines as p53-MDM2 protein-protein interaction inhibitors.

Guo Z, Zhuang C, Zhu L, Zhang Y, Yao J, Dong G, Wang S, Liu Y, Chen H, Sheng C, Miao Z, Zhang W.

Eur J Med Chem. 2012 Oct;56:10-6. doi: 10.1016/j.ejmech.2012.08.003.

PMID:
22940704
5.

Design, synthesis and biological evaluation of sulfamide and triazole benzodiazepines as novel p53-MDM2 inhibitors.

Yu Z, Zhuang C, Wu Y, Guo Z, Li J, Dong G, Yao J, Sheng C, Miao Z, Zhang W.

Int J Mol Sci. 2014 Sep 5;15(9):15741-53. doi: 10.3390/ijms150915741.

6.

Synthesis and biological evaluation of thio-benzodiazepines as novel small molecule inhibitors of the p53-MDM2 protein-protein interaction.

Zhuang C, Miao Z, Zhu L, Zhang Y, Guo Z, Yao J, Dong G, Wang S, Liu Y, Chen H, Sheng C, Zhang W.

Eur J Med Chem. 2011 Nov;46(11):5654-61. doi: 10.1016/j.ejmech.2011.09.043.

PMID:
21996465
7.

Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.

Zhuang C, Miao Z, Zhu L, Dong G, Guo Z, Wang S, Zhang Y, Wu Y, Yao J, Sheng C, Zhang W.

J Med Chem. 2012 Nov 26;55(22):9630-42. doi: 10.1021/jm300969t.

PMID:
23046248
8.

Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction.

Zheng GH, Shen JJ, Zhan YC, Yi H, Xue ST, Wang Z, Ji XY, Li ZR.

Eur J Med Chem. 2014 Jun 23;81:277-88. doi: 10.1016/j.ejmech.2014.05.027.

9.

Discovery of 1-arylpyrrolidone derivatives as potent p53-MDM2 inhibitors based on molecule fusing strategy.

Li J, Wu Y, Guo Z, Zhuang C, Yao J, Dong G, Yu Z, Min X, Wang S, Liu Y, Wu S, Zhu S, Sheng C, Miao Z, Zhang W.

Bioorg Med Chem Lett. 2014 Jun 15;24(12):2648-50. doi: 10.1016/j.bmcl.2014.04.063.

PMID:
24813735
10.

Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction.

Ding K, Lu Y, Nikolovska-Coleska Z, Wang G, Qiu S, Shangary S, Gao W, Qin D, Stuckey J, Krajewski K, Roller PP, Wang S.

J Med Chem. 2006 Jun 15;49(12):3432-5.

PMID:
16759082
11.

MDM2-p53 protein-protein interaction inhibitors: a-ring substituted isoindolinones.

Watson AF, Liu J, Bennaceur K, Drummond CJ, Endicott JA, Golding BT, Griffin RJ, Haggerty K, Lu X, McDonnell JM, Newell DR, Noble ME, Revill CH, Riedinger C, Xu Q, Zhao Y, Lunec J, Hardcastle IR.

Bioorg Med Chem Lett. 2011 Oct 1;21(19):5916-9. doi: 10.1016/j.bmcl.2011.07.084.

PMID:
21875801
12.

MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.

Tovar C, Graves B, Packman K, Filipovic Z, Higgins B, Xia M, Tardell C, Garrido R, Lee E, Kolinsky K, To KH, Linn M, Podlaski F, Wovkulich P, Vu B, Vassilev LT.

Cancer Res. 2013 Apr 15;73(8):2587-97. doi: 10.1158/0008-5472.CAN-12-2807.

13.

Synthesis and evaluation of novel orally active p53-MDM2 interaction inhibitors.

Miyazaki M, Naito H, Sugimoto Y, Yoshida K, Kawato H, Okayama T, Shimizu H, Miyazaki M, Kitagawa M, Seki T, Fukutake S, Shiose Y, Aonuma M, Soga T.

Bioorg Med Chem. 2013 Jul 15;21(14):4319-31. doi: 10.1016/j.bmc.2013.04.056.

PMID:
23685175
14.

Design, synthesis and CoMFA studies of N1-amino acid substituted 2,4,5-triphenyl imidazoline derivatives as p53-MDM2 binding inhibitors.

Hu C, Dou X, Wu Y, Zhang L, Hu Y.

Bioorg Med Chem. 2012 Feb 15;20(4):1417-24. doi: 10.1016/j.bmc.2012.01.003.

PMID:
22273545
15.

Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency.

Hardcastle IR, Liu J, Valeur E, Watson A, Ahmed SU, Blackburn TJ, Bennaceur K, Clegg W, Drummond C, Endicott JA, Golding BT, Griffin RJ, Gruber J, Haggerty K, Harrington RW, Hutton C, Kemp S, Lu X, McDonnell JM, Newell DR, Noble ME, Payne SL, Revill CH, Riedinger C, Xu Q, Lunec J.

J Med Chem. 2011 Mar 10;54(5):1233-43. doi: 10.1021/jm1011929.

PMID:
21314128
16.

MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53.

Canner JA, Sobo M, Ball S, Hutzen B, DeAngelis S, Willis W, Studebaker AW, Ding K, Wang S, Yang D, Lin J.

Br J Cancer. 2009 Sep 1;101(5):774-81. doi: 10.1038/sj.bjc.6605199.

17.

Design, synthesis and biological evaluation of novel potent MDM2/p53 small-molecule inhibitors.

Ivanenkov YA, Vasilevski SV, Beloglazkina EK, Kukushkin ME, Machulkin AE, Veselov MS, Chufarova NV, Chernyaginab ES, Vanzcool AS, Zyk NV, Skvortsov DA, Khutornenko AA, Rusanov AL, Tonevitsky AG, Dontsova OA, Majouga AG.

Bioorg Med Chem Lett. 2015 Jan 15;25(2):404-9. doi: 10.1016/j.bmcl.2014.09.070.

PMID:
25479770
18.

Prospective virtual screening for novel p53-MDM2 inhibitors using ultrafast shape recognition.

Patil SP, Ballester PJ, Kerezsi CR.

J Comput Aided Mol Des. 2014 Feb;28(2):89-97. doi: 10.1007/s10822-014-9732-4.

PMID:
24554192
19.

Discovery of a new small-molecule inhibitor of p53-MDM2 interaction using a yeast-based approach.

Leão M, Pereira C, Bisio A, Ciribilli Y, Paiva AM, Machado N, Palmeira A, Fernandes MX, Sousa E, Pinto M, Inga A, Saraiva L.

Biochem Pharmacol. 2013 May 1;85(9):1234-45. doi: 10.1016/j.bcp.2013.01.032.

PMID:
23428467
20.

MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.

Wang J, Zheng T, Chen X, Song X, Meng X, Bhatta N, Pan S, Jiang H, Liu L.

J Gastroenterol Hepatol. 2011 Feb;26(2):371-7. doi: 10.1111/j.1440-1746.2010.06440.x.

PMID:
21261729

Supplemental Content

Support Center